Prediction and management of hyperkalemia across the spectrum of chronic kidney disease

Seminars in Nephrology

Volumn 34, Issue 3, 2014, Pages 333-339

  Lazich, Ivana ^a   Bakris, George L ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Diabetes; Hyperkalemia; Hypertension; Kidney; Nephropathy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BICARBONATE; CALCINEURIN INHIBITOR; COTRIMOXAZOLE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FLUDROCORTISONE; HEPARIN; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PATIROMER; PLACEBO; POLYSTYRENESULFONATE SODIUM; POTASSIUM; RAMIPRIL; RENIN INHIBITOR; SORBITOL; SPIRONOLACTONE; TELMISARTAN; UREA; VALSARTAN; MINERALOCORTICOID ANTAGONIST;

ACIDOSIS; ADD ON THERAPY; AGE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIARRHEA; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; ESTIMATED GLOMERULUS FILTRATION RATE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; INTESTINE NECROSIS; NAUSEA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; UREA NITROGEN BLOOD LEVEL; CHRONIC KIDNEY FAILURE; COMPLICATION; DRUG EFFECTS; METABOLISM;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERKALEMIA; MINERALOCORTICOID RECEPTOR ANTAGONISTS; POTASSIUM; RENAL INSUFFICIENCY, CHRONIC;

EID: 84903955528     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2014.04.008     Document Type: Review

References (68)

1. Jain N., Kotla S., Little B.B., et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012, 109:1510-1513.
2. Einhorn L.M., Zhan M., Hsu V.D., et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009, 169:1156-1162.
3. Weir M.R., Rolfe M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 2010, 5:531-548.
4. Takaichi K., Takemoto F., Ubara Y., Mori Y. Analysis of factors causing hyperkalemia. Intern Med 2007, 46:823-829.
5. Kuijvenhoven M.A., Haak E.A., Gombert-Handoko K.B., Crul M. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia. Int J Clin Pharm 2013, 35:1099-1104.
6. Hou F.F., Zhang X., Zhang G.H., et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006, 354:131-140.
7. Sarafidis P.A., Bakris G.L. Renin-angiotensin blockade and kidney disease. Lancet 2008, 372:511-512.
8. Schlueter W., Keilani T., Batlle D.C. Tissue renin angiotensin systems: theoretical implications for the development of hyperkalemia using angiotensin-converting enzyme inhibitors. Am J Med Sci 1994, 307(Suppl 1):S81-S86.
9. Musso C.G. Potassium metabolism in patients with chronic kidney disease (CKD), part I: patients not on dialysis (stages 3-4). Int Urol Nephrol 2004, 36:465-468.
10. Gennari F.J., Segal A.S. Hyperkalemia: an adaptive response in chronic renal insufficiency. Kidney Int 2002, 62:1-9.
11. Welling P.A. Regulation of potassium channel trafficking in the distal nephron. Curr Opin Nephrol Hypertens 2013, 22:559-565.
12. Uribarri J., Oh M.S., Carroll H.J. Hyperkalemia in diabetes mellitus. J Diabet Complications 1990, 4:3-7.
13. Taal M, Chertow G, Marsden P, Skorecki K, Yu A, Brenner B. Adaptation to nephron loss and mechanisms of progression in chronic kidney disease. In: Brenner BM, Rector F (eds.): The kidney, 9th ed. Philadelphia: Saunders; 2011, pp. 893-915.
14. Welling P.A. Regulation of renal potassium secretion: molecular mechanisms. Semin Nephrol 2013, 33:215-228.
15. Oh M.S., Carroll H.J., Clemmons J.E., Vagnucci A.H., Levison S.P., Whang E.S. A mechanism for hyporeninemic hypoaldosteronism in chronic renal disease. Metabolism 1974, 23:1157-1166.
16. Palmer B.F. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004, 351:585-592.
17. Hene R.J., Boer P., Koomans H.A., Mees E.J. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982, 21:98-101.
18. Drawz P.E., Babineau D.C., Rahman M. Metabolic complications in elderly adults with chronic kidney disease. J Am Geriatr Soc 2012, 60:310-315.
19. Weinberg J.M., Appel L.J., Bakris G., et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 2009, 169:1587-1594.
20. Sarafidis P.A., Blacklock R., Wood E., et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol 2012, 7:1234-1241.
21. Maschio G., Alberti D., Janin G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996, 334:939-945.
22. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857-1863. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
23. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
24. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329:1456-1462.
25. Wright J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288:2421-2431.
26. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
27. Keilani T., Danesh F.R., Schlueter W.A., Molteni A., Batlle D. A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. Am J Kidney Dis 1999, 33:450-457.
28. Raebel M.A. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther 2012, 30:e156-e166.
29. Moranne O., Froissart M., Rossert J., et al. Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol 2009, 20:164-171.
30. Fink J.C. Chronic kidney disease: the effect of CKD therapies on serum potassium levels. Nat Rev Nephrol 2010, 6:633-634.
31. Reardon L.C., Macpherson D.S. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? Arch Intern Med 1998, 158:26-32.
32. Parving H.H., Brenner B.M., McMurray J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012, 367:2204-2213.
33. Fried L.F., Emanuele N., Zhang J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013, 369:1892-1903.
34. Khosla N., Kalaitzidis R., Bakris G.L. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol 2009, 30:418-424.
35. Mehdi U.F., Adams-Huet B., Raskin P., Vega G.L., Toto R.D. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009, 20:2641-2650.
36. Heshka J., Ruzicka M., Hiremath S., McCormick B.B. Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy. J Am Soc Hypertens 2010, 4:295-301.
37. Boesby L., Elung-Jensen T., Klausen T.W., Strandgaard S., Kamper A.L. Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study. PLoS One 2011, 6:e26904.
38. Roscioni S.S., de Zeeuw D., Bakker S.J., Lambers Heerspink H.J. Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol 2012, 8:691-699.
39. Bomback A.S., Kshirsagar A.V., Amamoo M.A., Klemmer P.J. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008, 51:199-211.
40. Bakris G.L., Oparil S., Purkayastha D., Yadao A.M., Alessi T., Sowers J.R. Randomized study of antihypertensive efficacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 2013, 15:92-100.
41. Chrysostomou A., Pedagogos E., MacGregor L., Double-blind Becker GJ. placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006, 1:256-262.
42. Bianchi S., Bigazzi R., Campese V.M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006, 70:2116-2123.
43. Buchner N., Banas B., Kramer B.K. Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med 2008, 359:426.
44. MacKinnon M., Shurraw S., Akbari A., Knoll G.A., Jaffey J., Clark H.D. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006, 48:8-20.
45. Parving H.H., Brenner B.M., McMurray J.J., et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012, 367:2204-2213.
46. Mann J.F., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372:547-553.
47. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43 Suppl 1:S1-290.
48. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235.
49. Raebel M.A., McClure D.L., Simon S.R., et al. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf 2007, 16:55-64.
50. Raebel M.A., McClure D.L., Chan K.A., et al. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?. Ann Pharmacother 2007, 41:193-200.
51. Raebel M.A., Ross C., Xu S., et al. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med 2010, 25:326-333.
52. Cruz C.S., Cruz A.A., Marcilio de Souza C.A. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant 2003, 18:1814-1819.
53. Saito M., Takada M., Hirooka K., Isobe F., Yasumura Y. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. J Clin Pharm Ther 2005, 30:603-610.
54. Ponda M.P., Hostetter T.H. Aldosterone antagonism in chronic kidney disease. Clin J Am Soc Nephrol 2006, 1:668-677.
55. Zannad F., Gattis S.W., Rossignol P., et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012, 33:2782-2795.
56. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
57. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
58. Bakris G.L., Siomos M., Richardson D., et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Kidney Int 2000, 58:2084-2092.
59. Zipser R.D., Henrich W.L. Implications of nonsteroidal anti-inflammatory drug therapy. Am J Med 1986, 80:78-84.
60. Oster J.R., Singer I., Fishman L.M. Heparin-induced aldosterone suppression and hyperkalemia. Am J Med 1995, 98:575-586.
61. Fenton F., Smally A.J., Laut J. Hyperkalemia and digoxin toxicity in a patient with kidney failure. Ann Emerg Med 1996, 28:440-441.
62. Marinella M.A. Trimethoprim-induced hyperkalemia: an analysis of reported cases. Gerontology 1999, 45:209-212.
63. Winkler A.W., Hoff H.E., Smith P.K. Factors affecting the toxicity of potassium. Am J Physiol 1939, 127:430-435.
64. Sterns R.H., Rojas M., Bernstein P., Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?. J Am Soc Nephrol 2010, 21:733-735.
65. McGowan C.E., Saha S., Chu G., Resnick M.B., Moss S.F. Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol. South Med J 2009, 102:493-497.
66. Pitt B., Anker S.D., Bushinsky D.A., Kitzman D.W., Zannad F., Huang I.Z. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011, 32:820-828.
67. Zehnder C., Gutzwiller J.P., Huber A., Schindler C., Schneditz D. Low-potassium and glucose-free dialysis maintains urea but enhances potassium removal. Nephrol Dial Transplant 2001, 16:78-84.
68. Ruggenenti P., Perna A., Gherardi G., Gaspari F., Benini R., Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 1998, 352:1252-1256.